1.
Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2.
Research Methodology
2.1.
Objective of the Study
2.2.
Baseline Methodology
2.3.
Key Industry Partners
2.4.
Major Association and Secondary Sources
2.5.
Forecasting Methodology
2.6.
Data Triangulation & Validation
2.7.
Assumptions and Limitations
3.
Executive Summary
3.1. Overview of the
Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4.
Voice of Customer
5. Global T-Cell Lymphoma
Market Outlook
5.1.
Market Size & Forecast
5.1.1.
By Value
5.2.
Market Share & Forecast
5.2.1.
By Type of Lymphoma (Peripheral T-cell Lymphoma (Cutaneous
T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell
Lymphoma, Other Types of Lymphoma), T-cell Lymphoblastic Lymphoma)
5.2.2.
By Type of Therapy (Radiotherapy, Chemotherapy,
Immunotherapy, Stem Cell Transplantation, Other Types of Therapies)
5.2.3.
By Region
5.2.4.
By Company (2022)
5.3.
Market Map
6. Asia Pacific T-Cell Lymphoma
Market Outlook
6.1.
Market Size & Forecast
6.1.1.
By Value
6.2.
Market Share & Forecast
6.2.1.
By Type of Lymphoma
6.2.2.
By Type of Therapy
6.2.3.
By Country
6.3.
Asia Pacific: Country Analysis
6.3.1.
China T-Cell Lymphoma Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Type
of Lymphoma
6.3.1.2.2.
By Type
of Therapy
6.3.2.
India T-Cell Lymphoma Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Type
of Lymphoma
6.3.2.2.2.
By Type
of Therapy
6.3.3.
Australia T-Cell Lymphoma Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Type
of Lymphoma
6.3.3.2.2.
By Type
of Therapy
6.3.4.
Japan T-Cell Lymphoma Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Type
of Lymphoma
6.3.4.2.2.
By Type
of Therapy
6.3.5.
South Korea T-Cell Lymphoma Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Type
of Lymphoma
6.3.5.2.2.
By Type
of Therapy
7. Europe T-Cell Lymphoma
Market Outlook
7.1.
Market Size & Forecast
7.1.1.
By Value
7.2.
Market Share & Forecast
7.2.1.
By Type
of Lymphoma
7.2.2.
By Type
of Therapy
7.2.3.
By Country
7.3.
Europe: Country Analysis
7.3.1.
France T-Cell Lymphoma Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Type
of Lymphoma
7.3.1.2.2.
By Type
of Therapy
7.3.2.
Germany T-Cell Lymphoma Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Type
of Lymphoma
7.3.2.2.2.
By Type
of Therapy
7.3.3.
Spain T-Cell Lymphoma Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Type
of Lymphoma
7.3.3.2.2.
By Type
of Therapy
7.3.4.
Italy T-Cell Lymphoma Market Outlook
7.3.4.1.
Market Size & Forecast
7.3.4.1.1.
By Value
7.3.4.2.
Market Share & Forecast
7.3.4.2.1.
By Type
of Lymphoma
7.3.4.2.2.
By Type
of Therapy
7.3.5.
United Kingdom T-Cell Lymphoma Market Outlook
7.3.5.1.
Market Size & Forecast
7.3.5.1.1.
By Value
7.3.5.2.
Market Share & Forecast
7.3.5.2.1.
By Type
of Lymphoma
7.3.5.2.2.
By Type
of Therapy
8. North America T-Cell
Lymphoma Market Outlook
8.1.
Market Size & Forecast
8.1.1.
By Value
8.2.
Market Share & Forecast
8.2.1.
By Type
of Lymphoma
8.2.2.
By Type
of Therapy
8.2.3.
By Country
8.3.
North America: Country Analysis
8.3.1.
United States T-Cell Lymphoma Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Type
of Lymphoma
8.3.1.2.2.
By Type
of Therapy
8.3.2.
Mexico T-Cell Lymphoma Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Type
of Lymphoma
8.3.2.2.2.
By Type
of Therapy
8.3.3.
Canada T-Cell Lymphoma Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Type
of Lymphoma
8.3.3.2.2.
By Type
of Therapy
9. South America T-Cell
Lymphoma Market Outlook
9.1.
Market Size & Forecast
9.1.1.
By Value
9.2.
Market Share & Forecast
9.2.1.
By Type
of Lymphoma
9.2.2.
By Type
of Therapy
9.2.3.
By Country
9.3.
South America: Country Analysis
9.3.1.
Brazil T-Cell Lymphoma Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Type
of Lymphoma
9.3.1.2.2.
By Type
of Therapy
9.3.2.
Argentina T-Cell Lymphoma Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Type
of Lymphoma
9.3.2.2.2.
By Type
of Therapy
9.3.3.
Colombia T-Cell Lymphoma Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Type
of Lymphoma
9.3.3.2.2.
By Type
of Therapy
10. Middle East and Africa
T-Cell Lymphoma Market Outlook
10.1.
Market Size & Forecast
10.1.1. By Value
10.2.
Market Share & Forecast
10.2.1. By Type of Lymphoma
10.2.2. By Type of Therapy
10.2.3. By Country
10.3.
MEA: Country Analysis
10.3.1. South Africa T-Cell Lymphoma
Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1.
By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1.
By Type
of Lymphoma
10.3.1.2.2.
By Type
of Therapy
10.3.2. Saudi Arabia T-Cell Lymphoma
Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1.
By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1.
By Type
of Lymphoma
10.3.2.2.2.
By Type
of Therapy
10.3.3. UAE T-Cell Lymphoma
Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1.
By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1.
By Type
of Lymphoma
10.3.3.2.2.
By Type
of Therapy
11.
Market Dynamics
11.1.
Drivers
11.2.
Challenges
12.
Market Trends & Developments
12.1.
Recent Developments
12.2.
Product Launches
12.3.
Mergers & Acquisitions
13.
Global T-Cell Lymphoma Market: SWOT Analysis
14. Porter’s Five Forces
Analysis
14.1.
Competition in the Industry
14.2.
Potential of New Entrants
14.3.
Power of Suppliers
14.4.
Power of Customers
14.5.
Threat of Substitute Product
15.
PESTLE Analysis
16.
Competitive Landscape
16.1.
Mundipharma International
16.1.1. Business Overview
16.1.2. Company Snapshot
16.1.3. Products &
Services
16.1.4. Financials (In case
of listed companies)
16.1.5. Recent Developments
16.1.6. SWOT Analysis
16.2.
Bristol-Myers Squibb Company
16.2.1. Business Overview
16.2.2. Company Snapshot
16.2.3. Products &
Services
16.2.4. Financials (In case
of listed companies)
16.2.5. Recent Developments
16.2.6. SWOT Analysis
16.3.
Genmab AS
16.3.1. Business Overview
16.3.2. Company Snapshot
16.3.3. Products &
Services
16.3.4. Financials (In case
of listed companies)
16.3.5. Recent Developments
16.3.6. SWOT Analysis
16.4.
Johnson & Johnson (Janssen Pharmaceuticals Inc.)
16.4.1. Business Overview
16.4.2. Company Snapshot
16.4.3. Products &
Services
16.4.4. Financials (In case
of listed companies)
16.4.5. Recent Developments
16.4.6. SWOT Analysis
16.5.
Merck & Co. Inc.
16.5.1. Business Overview
16.5.2. Company Snapshot
16.5.3. Products &
Services
16.5.4. Financials (In case
of listed companies)
16.5.5. Recent Developments
16.5.6. SWOT Analysis
16.6.
F. Hoffmann-La Roche Ltd
16.6.1. Business Overview
16.6.2. Company Snapshot
16.6.3. Products &
Services
16.6.4. Financials (In case
of listed companies)
16.6.5. Recent Developments
16.6.6. SWOT Analysis
16.7.
Novartis AG
16.7.1. Business Overview
16.7.2. Company Snapshot
16.7.3. Products &
Services
16.7.4. Financials (In case
of listed companies)
16.7.5. Recent Developments
16.7.6. SWOT Analysis
16.8.
Autolus Therapeutics PLC
16.8.1. Business Overview
16.8.2. Company Snapshot
16.8.3. Products &
Services
16.8.4. Financials (In case
of listed companies)
16.8.5. Recent Developments
16.8.6. SWOT Analysis
16.9.
Acrotech Biopharma Inc.
16.9.1. Business Overview
16.9.2. Company Snapshot
16.9.3. Products &
Services
16.9.4. Financials (In case
of listed companies)
16.9.5. Recent Developments
16.9.6. SWOT Analysis
16.10.
Macopharma International GmbH
16.10.1. Business Overview
16.10.2. Company Snapshot
16.10.3. Products &
Services
16.10.4. Financials (In case
of listed companies)
16.10.5. Recent Developments
16.10.6. SWOT Analysis
17. Strategic Recommendations
18. About Us & Disclaimer